CClinicalTrials.gg
Status unknownNCT02830867Updated Jan 10, 2018

Review of French Cases of Glutathione Synthetase Deficiency

An observational study in The Glutathione Synthetase Deficiency, sponsored by University Hospital, Strasbourg, France. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-10.

Sponsored by University Hospital, Strasbourg, France · Observational

The sponsor has not verified this record recently (last verified Jan 2016), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

The glutathione synthetase deficiency, inborn error of metabolism of autosomal recessive inheritance, is a rare disease (70 patients described in the world). The outcome of these patients and potential complications of this disease are not, to date, yet all known and described.

02

Conditions studied

  • The Glutathione Synthetase Deficiency

Keywords

  • glutathione
  • glutathione synthetase deficiency
  • autosomal inheritance
  • recessive
03

In context

Amino Acid Metabolism, Inborn Errors

29 studies on the registry are indexed under Amino Acid Metabolism, Inborn Errors; 8 are open to participants now.

This study's planned enrollment of 100 is above the median of 60 across 11 observational studies indexed under Amino Acid Metabolism, Inborn Errors.

Browse Amino Acid Metabolism, Inborn Errors studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All patients followed in the French hospital centers the diagnosis of glutathione synthetase deficiency has been proven by assay of residual enzyme activity or identifying a mutation of the glutathione synthetase gene

Inclusion criteria

  • All patients followed in the French hospital centers the diagnosis of glutathione synthetase deficiency has been proven by assay of residual enzyme activity or identifying a mutation of the glutathione synthetase gene

Exclusion criteria

Exclusion criteria:

  • No formal proof of glutathione synthetase deficiency
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Immunologically determining human acid glutathione S-transferase in a human assay sample

    Time frame: 1 hour after hospitalization

07

Study locations

1 of 1 sites recruiting
  • Service D'Urgences Medicales Pediatriques
    Strasbourg, 67091, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02830867
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Jul 13, 2016
Start date
Jul 2016
Primary completion
Oct 2018 (estimated)
Completion
Oct 2018 (estimated)
Last update
Jan 10, 2018

Study contacts

Didier EYER, MD
Contact
didier.eyer@chru-strasbourg.fr
33 (0)3.88.12.81.18
Claire BANSEPT
Contact
claire.bansept@chru-strasbourg.fr
33 (0)3.88.12.77.57

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion